ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9735-9745

  Hogarty, Michael D ^a,e   Norris, Murray D ^b   Davis, Kimberly ^a   Liu, Xueyuan ^a   Evageliou, Nicholas F ^c   Hayes, Candace S ^a   Pawel, Bruce ^a   Guo, Rong ^a   Zhao, Huaqing ^a   Sekyere, Eric ^b   Keating, Joanna ^b   Thomas, Wayne ^b   Ngan, Ching Cheng ^b   Murray, Jayne ^b   Smith, Janice ^b   Sutton, Rosemary ^b   Venn, Nicola ^b   London, Wendy B ^d   Buxton, Allen ^d   Gilmour, Susan K ^c   Marshall, Glenn M ^b   Haber, Michelle ^b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d Children's Oncology Group Statistics ^*  (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EFLORNITHINE; POLYAMINE; TRANSCRIPTOME;

AMD1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLAST; NEUROBLASTOMA; NONHUMAN; OAZ2 GENE; ONCOGENE; ONCOGENE C MYB; ONCOGENE ODC1; PRIORITY JOURNAL; SMOX GENE; SMS GENE; SRM GENE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOGENIC POLYAMINES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; CISPLATIN; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG SYNERGISM; EFLORNITHINE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ORNITHINE DECARBOXYLASE;

EID: 57149098994     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6866     Document Type: Article

References (48)

1. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
3. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000;18:18-26.
4. Kohl NE, Kanda N, Schreck RR, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-67.
5. Liu X, Mazanek P, Dam V, et al. Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008;27:1478-88.
6. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.
7. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 2004;4:562-8.
8. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278:12563-73.
9. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-8.
10. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992;360:355-8.
11. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48:759-74.
12. Bettuzzi S, Davalli P, Astancolle S, et al. Coordinate changes of polyamine metabolism regulatory proteins during the cell cycle of normal human dermal fibroblasts. FEBS Lett 1999;446:18-22.
13. Shirahata A, Pegg AE. Regulation of S-adenosylmethionine decarboxylase activity in rat liver and prostate. J Biol Chem 1985;260:9583-8.
14. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
15. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005;7:433-44.
16. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006;24:2891-6.
17. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
18. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and demonstrates that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-62.
19. Manduchi E, Grant GR, McKenzie SE, Overton GC, Surrey S, Stoeckert CJ, Jr. Generation of patterns from gene expression data by assigning confidence to differentially expressed genes. Bioinformatics 2000;16:685-98.
20. Greshock J, Naylor TL, Margolin A, et al. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 2004;14:179-87.
21. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936-49.
22. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53.
23. Thompson PM, Maris JM, Hogarty MD, et al. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 2001;61:679-86.
24. Tajiri T, Liu X, Thompson PM, et al. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 2003;9:3345-55.
25. Xing JZ, Zhu L, Jackson JA, et al. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 2005;18:154-61.
26. Burkhart CA, Cheng AJ, Madafiglio J, et al. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 2003;95:1394-403.
27. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101:12664-9.
28. Weiss WA, Aldape K, Bishop JM. Targeted expression of NMYC causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
29. Koza RA, Megosh LC, Palmieri M, O'Brien TG. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas. Carcinogenesis 1991;12:1619-25.
30. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13.
31. Schipper RG, Romain N, Otten AA, Tan J, Lange WP, Verhofstad AA. Immunocytochemical detection of ornithine decarboxylase. J Histochem Cytochem 1999;47:1395-404.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
33. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;34:187-220.
34. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
35. Weber A, Imisch P, Bergmann E, Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 2004;22:2681-90.
36. Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 1990;5:1821-7.
37. 1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-18.
38. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-73.
39. Mosse YP, Greshock J, Margolin A, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 2005;43:390-403.
40. Chesler L, Goldenberg DD, Seales IT, et al. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007;67:9435-42.
41. Wartiovaara K, Barnabe-Heider F, Miller FD, Kaplan DR. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J Neurosci 2002;22:815-24.
42. Lan L, Trempus C, Gilmour SK. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res 2000;60:5696-703.
43. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
44. Keller UB, Old JB, Dorsey FC, et al. Myc targets Cks1 to provoke the suppression of p27(Kip1), proliferation and lymphomagenesis. EMBO J 2007;26:2562-74.
45. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem (Tokyo) 2006;139:27-33.
46. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373-90.
47. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
48. Varma R, Hector S, Greco WR, et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 2007;59:711-23.